Aralez Pharmaceuticals Inc. (ARLZ) Shares Down 0.4%
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) was down 0.4% during trading on Friday . The company traded as low as $4.95 and last traded at $5.00, with a volume of 511,983 shares. The stock had previously closed at $5.02.
A number of equities research analysts have commented on ARLZ shares. Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th. Guggenheim reiterated a “buy” rating and set a $12.00 price target on shares of Aralez Pharmaceuticals in a report on Monday, August 15th.
The stock’s 50 day moving average is $4.33 and its 200 day moving average is $4.19. The stock’s market capitalization is $326.20 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. The firm’s quarterly revenue was up 142.3% on a year-over-year basis. Equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($0.98) earnings per share for the current year.
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.